4//SEC Filing
Nagendran Sukumar 4
Accession 0001415889-25-024369
CIK 0001806310other
Filed
Sep 11, 8:00 PM ET
Accepted
Sep 12, 4:15 PM ET
Size
9.3 KB
Accession
0001415889-25-024369
Insider Transaction Report
Form 4
Nagendran Sukumar
DirectorPresident and Head of R&D
Transactions
- Sale
Common Stock
2025-09-10$3.23/sh−200,000$646,000→ 1,006,439 total - Exercise/Conversion
Common Stock
2025-09-10$0.70/sh+41,150$28,760→ 1,206,439 total - Exercise/Conversion
Employee Stock Option (right to buy)
2025-09-10−41,150→ 292,855 totalExercise: $0.70Exp: 2033-12-14→ Common Stock (41,150 underlying)
Footnotes (3)
- [F1]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.165 to $3.31 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The shares underlying the option vested or shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date.
Documents
Issuer
Taysha Gene Therapies, Inc.
CIK 0001806310
Entity typeother
Related Parties
1- filerCIK 0001665124
Filing Metadata
- Form type
- 4
- Filed
- Sep 11, 8:00 PM ET
- Accepted
- Sep 12, 4:15 PM ET
- Size
- 9.3 KB